Melatonin and Melatoninergic Drugs as Therapeutic Agents: Ramelteon and Agomelatine, the Two Most Promising Melatonin Receptor Agonists

Publisher： Bentham Science Publishers

E-ISSN： 2212-3334|1|2|142-151

ISSN： 1872-2148

Source： Recent Patents on Endocrine, Metabolic & Immune Drug Discovery, Vol.1, Iss.2, 2007-06, pp. : 142-151

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The Therapeutic Potential of Melatonin in Neurological Disorders

By  

Recent Patents on Endocrine, Metabolic & Immune Drug Discovery, Vol. 3, Iss. 1, 2009-01 ,pp. : 60-64

Bentham Science Publishers

Access to resources Recommend Favorite

Melatonin Effects on Plasmodium Life Cycle: New Avenues for Therapeutic Approach

By  

Recent Patents on Endocrine, Metabolic & Immune Drug Discovery, Vol. 6, Iss. 2, 2012-05 ,pp. : 139-147

Bentham Science Publishers

Access to resources Recommend Favorite

Novel Promising Therapeutic Agents in Multiple Sclerosis

By  

Recent Patents on Inflammation & Allergy Drug Discovery, Vol. 1, Iss. 3, 2007-11 ,pp. : 218-224

Bentham Science Publishers

Access to resources Recommend Favorite

Melatonin, Immune Function and Cancer

By  

Recent Patents on Endocrine, Metabolic & Immune Drug Discovery, Vol. 5, Iss. 2, 2011-05 ,pp. : 109-123

Bentham Science Publishers

Access to resources Recommend Favorite

Relevance of the Chronobiological and Non-chronobiological Actions of Melatonin for Enhancing Therapeutic Efficacy in Neurodegenerative Disorders

By  

Recent Patents on Endocrine, Metabolic & Immune Drug Discovery, Vol. 5, Iss. 2, 2011-05 ,pp. : 91-99

Bentham Science Publishers

Access to resources Recommend Favorite